Azitra Receives Notice of Non-Compliance from NYSE American

Core Viewpoint - Azitra, Inc. has received a notice from NYSE American regarding non-compliance with continued listing standards due to insufficient stockholders' equity, requiring a plan for compliance by October 31, 2025 [1][2]. Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on precision dermatology, with its lead program ATR-12 aimed at treating Netherton syndrome, a rare skin disease [4]. - The company also has an advanced program ATR-04 for treating EGFR inhibitor-associated rash, which has received Fast Track designation from the FDA [4]. Compliance and Future Plans - Azitra plans to submit a compliance plan to the Exchange and is exploring multiple funding avenues to meet the listing requirements [2]. - If the plan is accepted, Azitra will undergo periodic reviews to ensure compliance [2]. Current Status - The notice from the Exchange does not immediately affect the listing or trading of Azitra's common stock and does not impact its business operations or reporting requirements [3].